RESOLVING THE LEDGER
RESOLVING THE LEDGER
This is not a single article. It's every outletcovering this one event, gathered in one place — read AIPROPX's summary, see where the sources line up, then open any report at its origin.
By AIPROPX Editorial Desk · Published · Updated
Everything reported about this story, gathered from 5 sources. Read the summary below, then tap any source to open that report.
The companies have discussed a potential merger over several months, reports say.
Summary indexed by AIPROPX from CNBC’s reporting — the full article is one click away. Open at source →
5 outlets are covering this. Resolve the ledger to read what they collectively report — the common thread, in plain terms.
Every report on this story — read the summary of each, then open any at its source. AIPROPX summarizes and links; it never reproduces the original.
The companies have discussed a potential merger over several months, reports say.
Read this reportAstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
Read this report
Bristol Myers Squibb tie-up would be one of biggest-ever pharma deals and create world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker, AstraZeneca, is understood to be in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group. AstraZeneca, run by Pascal Soriot, its longtime chief executive, is the second-biggest listed company in the UK, with a market value of nearly £196bn before the news broke. BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, ...
Read this reportThe deal would create one of the world’s biggest pharmaceutical groups.
Read this reportAn original, deterministic readout — composed only from the computed coverage facts on this page. No interpretation, no rating; figures only.
AIPROPX has consolidated 5 reports from 5 outlets into a single canonical entry on “AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed.” The covered outlets are based across 4 regions — US, UK, International, and Other.
The earliest report in this entry came from The Straits Times (Aug 2, 2026, 20:04 UTC); the most recent came from CNBC (Aug 3, 2026, 11:35 UTC).
Comparing the wording across sources, 3 named entities are referenced by multiple outlets and the phrase recurring most across the coverage is “bristol myers”.
6 statements are carried by only one outlet within this set and are not echoed by the others.
Every figure above is a direct count of real published articles. AIPROPX indexes and compares the original reporting — it never rewrites, rates, or editorializes — and each publisher’s full article is always one click away.
Generated by AIPROPX from the source counts above. AIPROPX indexes and resolves coverage; the original publishers are credited and linked at origin in every report.
Coverage from 5 independent outlets across 4 regions — each view opens on its own page.
AIPROPX — “AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed” · https://www.aipropx.com/story/6b57fb5c45bb3e0802069eda5fd99954
Other events being covered across multiple sources right now.
Iran denies Trump claim that U.S-Iran negotiations begin today
10 outletsWhat the market is saying about the U.S. intervention to prop up the yen
6 outletsSpain's Ceuta overwhelmed as thousands remain after migrant border rush
4 outletsIran in talks with Oman over shipping route but not US, says Tehran
4 outletsMassive Attack banned from Singapore over Palestinian flag
21 outletsKorea Box Office: ‘Spider-Man: Brand New Day’ Captures 81% Market Share in Colossal Debut